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A B S T R A C T
Parkinson's disease is a neurodegenerative disorder partly caused by the loss of the dopamine neurons of the
nigrostriatal pathway. It is accompanied by motor as well as non-motor symptoms, including pain and de-
pression. The tail of the ventral tegmental area (tVTA) or rostromedial tegmental nucleus (RMTg) is a GABAergic
mesopontine structure that acts as a major inhibitory brake for the substantia nigra pars compacta (SNc) do-
pamine cells, thus controlling their neuronal activity and related motor functions. The present study tested the
influence of suppressing this tVTA brake on motor and non-motor symptoms in a rat model of Parkinson's
disease. Using behavioral approaches, we showed that male Sprague-Dawley rats with bilateral and partial 6-
hydroxydopamine SNc lesion displayed motor impairments in the rotarod test, impairments that were no more
present following a co-lesion of the tVTA. Using a larger set of behavioral tests, we then showed that such SNc
lesion also led to non-motor symptoms, including lower body weight, lower mechanical nociceptive thresholds
in the forceps test and lower thermal nociceptive thresholds in the incremented hot-plate test, and a decreased
sucrose preference in a 2-bottle choice paradigm. The excitotoxic co-lesion of the tVTA led to compensation of
body weight, mechanical nociceptive thresholds and anhedonia-like behavior. These findings illustrate the major
influence that the tVTA exerts on the dopamine system, modulating the motor and non-motor symptoms related
to a partial loss of dopamine cells.
1. Introduction
Parkinson's disease is a common and progressive neurodegenerative
disorder, mainly characterized by the loss of dopaminergic neurons of
the substantia nigra pars compacta (SNc) in the midbrain and by the
presence of cytoplasmic protein aggregates of α-synuclein (Lewy
bodies) in the affected brain areas. The neurodegeneration in
Parkinson's disease leads to a triad of motor symptoms including bra-
dykinesia, muscle rigidity and resting tremor. Likewise, a variety of
non-motor symptoms are related to the progression of the disease, in-
cluding sleep disorders, gastrointestinal and autonomic symptoms
(nausea, constipation), sensory symptoms (olfactory impairment), pain
and neuropsychiatric symptoms (depression, anxiety) (Blanchet and
Brefel-Courbon, 2017; Chaudhuri et al., 2006; Faivre et al., 2019; Park
and Stacy, 2009). The clinical diagnosis is mainly based on the motor
symptoms which are noticeable when the disease is already advanced,
whereas pain and emotional disturbances can be among prodromal
symptoms whose early identification might facilitate early diagnosis
and treatment (Antonini et al., 2018; Marsili et al., 2018).
Various animal models of Parkinson's disease have been established,
attempting to reproduce parkinsonian-like symptoms (for review, see
Faivre et al., 2019), including motor and non-motor ones (Vingill et al.,
2018). The 6-hydroxydopamine (6-OHDA) models have been classically
used in Parkinson's disease studies, as the direct brain administration of
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this toxin allows a destruction of dopamine neurons terminals and soma
(Ungerstedt, 1968), hence leading to motor symptoms comparable to
those appearing in humans (Gubellini and Kachidian, 2015; Ungerstedt,
1968), as well as to non-motor symptoms (Bonito-Oliva et al., 2014; Faivre
et al., 2019). Moreover, partial lesions with 6-OHDA might also provide a
model of early stages of the disease (Gubellini and Kachidian, 2015).
The tail of the ventral tegmental area (tVTA) (Kaufling et al., 2009;
Perrotti et al., 2005), also named rostromedial tegmental nucleus
(RMTg) (Jhou et al., 2009a, 2009b), is a GABAergic mesopontine
structure that exerts an important inhibitory control on the midbrain
dopamine neurons of the ventral tegmental area (VTA) and the SNc
(Bourdy and Barrot, 2012; Sanchez-Catalan et al., 2014). The tVTA
functions have been explored in the response to drugs of abuse
(Kaufling et al., 2010a, 2010b; Jalabert et al., 2011; Lecca et al., 2011,
2012; Matsui and Williams, 2011; Jhou et al., 2012, 2013; Kaufling and
Aston-Jones, 2015), in avoidance behaviors (Jhou et al., 2009a; Li
et al., 2019; Sánchez-Catalán et al., 2017; Stamatakis and Stuber,
2012), in reward prediction error (Hong et al., 2011) and in the control
of motor function (Bourdy et al., 2014). Regarding the tVTA role in
motor function, a tVTA-nigrostriatal pathway has been described, as
well as the inhibitory electrophysiological influence of the tVTA on SNc
dopamine neurons (Bourdy et al., 2014). At behavioral level, the tVTA
ablation can compensate the amphetamine-induced rotation bias after
partial ipsilateral lesion of the SNc (Bourdy et al., 2014). Moreover,
animals with a bilateral ablation of the tVTA display increased motor
performances and better motor skill learning compared to sham animals
in a rotarod task (Bourdy et al., 2014). Thus, the experimental evidence
supports an influence of the tVTA on basal ganglia circuitry.
In the present study, we explored whether a bilateral tVTA ablation
could improve the deficit in motor coordination observed following the
bilateral partial loss of SNc dopamine neurons. We then completed the
behavioral analysis of the model to include some non-motor symptoms,
and we tested the impact of tVTA lesion on some of these symptoms.
2. Material and methods
2.1. Ethical approval
All procedures involving animals were performed in accordance
with the Centre National de la Recherche Scientifique (CNRS) and the
European Union directive (2010/63/EU) on the protection of animals
used for scientific purposes. Experiments were approved by the
Institutional Animal Care and Use Committee of Strasbourg (CREMEAS
– France; #02051.01).
2.2. Animals
Experiments were performed in adult male Sprague-Dawley rats
(Janvier, France). The rats were habituated to the facilities for at least
one week before starting the procedures, and were 7–9 weeks old (i.e
200-300 g) at surgery time. They were housed 2 per cage, under stan-
dard conditions (22 °C, 12-h light/dark cycle) and were provided with
food and water ad libitum.
2.3. Drugs
Ibotenic acid (1% in phosphate-buffered saline (PBS) 0.1 M; 0.3 μL per
side) was injected bilaterally into the tVTA using Hamilton syringes with
33-gauge needles. The syringe plunger was manually pushed at a rate of
0.05 μL every 30 s. The 6-hydroxydopamine hydrochloride (6-OHDA;
2.5 μg/μL in 0.9% NaCl with 0.01% ascorbic acid) was injected bilaterally
into the SNc (1.75 μL per side for partial lesion). The syringe plunger was
manually pushed at a rate of 0.5 μL every 30 s and 0.25 μL for the last
push. Needles were then let in place 5 min before removal to allow so-
lution diffusion. When no lesion was performed (Sham groups), the
needle was just placed in the target brain area but nothing was injected.
2.4. Surgical procedures
2.4.1. Experiment 1
Rats were randomly assigned to 4 groups for bilateral surgery:
control (no lesion either of the tVTA or the SNc), SNc lesion (6-OHDA
into the SNc and no lesion in the tVTA), tVTA lesion (ibotenic acid into
the tVTA and no lesion in the SNc), and double lesion (both tVTA and
SNc lesion). Animals were anaesthetized under sodium pentobarbital
(50 mg/kg, intraperitoneal (i.p.); Ceva Santé Animale, Libourne,
France). The depth of anesthesia was controlled during surgery by
checking pedal reflex and a third of the initial dose was reinjected if
necessary. Before placing the animal in a stereotaxic frame (David Kopf,
Tujunga, CA), a local anesthetic (bupivacaine, 25 mg/kg; Mylan, Saint
Priest, France) and an anti-inflammatory drug (Metacam®, 1 mL/kg;
Boehringer Ingelheim/Rhein, Germany) were injected subcutaneously.
A hydrating gel (Ocry-gel, TVM Laboratories, Lempdes, France) was
regularly applied on animal's eyes to avoid dehydration. Stereotaxic
coordinates relative to bregma were adjusted to the animal weight,
coordinates (in mm) were as follows (Paxinos and Watson, 2014): tVTA,
anteroposterior (AP) = − 6.6, lateral (L) = ±1.3, ventral (V) = −
7.6,± 6° lateral angle and SNc, AP = − 5.2, L = ±2.2, V = −7.7.
Verticality was taken from the dura. After injection, the needle was left
in place for 5 min before removal. Following surgery, animals were kept
under a warming lamp for anesthesia recovery and later returned back
to the home cage. An oral anti-inflammatory treatment (Metacam®,
1 mL for 100 mL of water solution; Boehringer, Ingelheim/Rhein,
Germany) and a special palatable food (gel-diet mixed with baby food)
were available for 3 days post-surgery. After post-mortem control for
the extent of nigrostriatal lesion, 36 rats (spread over 3 experimental
waves) were retained for inclusion into behavioral analysis of tVTA
impact on motor coordination.
2.4.2. Experiment 2
Rats were randomly distributed in 2 groups: control (no lesion) and
SNc lesion (6-OHDA into the SNc). The surgical procedure was as de-
scribed above for experiment 1. After post-mortem control for the extent
of the 6-OHDA-induced lesion, 21 rats were retained for inclusion into
behavioral analysis.
2.4.3. Experiment 3
Rats were randomly assigned to 4 groups: control (no lesion), SNc
lesion (6-OHDA), tVTA lesion (ibotenic acid), and double lesion. The
surgical procedure was as described above for experiment 1. After post-
mortem control for the extent of lesion, 25 rats (spread over 2 experi-
mental waves) were retained for inclusion into behavioral analysis as-
sessing the impact of tVTA lesion on non-motor symptoms.
2.5. Behavioral tests
2.5.1. Rotarod
To evaluate the effect of lesions on motor coordination (experiment
1), animals were tested on the rotarod (Roto-Rod Series 8, IITC Life
Science). Before surgery, they underwent training sessions, with one
habituation session to the rotarod (5 min, 5 RPM) and three consecutive
sessions over three consecutive days under an accelerating speed ramp
(0–45 RPM, 180 s). After 7 to 10 days post-surgery, rotarod perfor-
mance was evaluated with three sessions over three consecutive days
under accelerated speed as described above. For each of the test days,
results are expressed as the mean latency to fall for trials on this day.
To control for motor deficits in 6-OHDA animals (experiment 2),
rotarod (Roto-Rod Series 8, IITC Life Science) performance was eval-
uated on week 12 after surgery, testing animals with four fixed speed
(5, 10, 15 and 20 RPM) and measuring the latency to fall.
2.5.2. Forceps
The mechanical sensitivity (experiments 2 & 3) was evaluated using
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digital calibrated forceps also referred to as rodent pincher-analgesia
meter (Société Bioseb, Chaville, France) as previously described (Luis-
Delgado et al., 2006). Shortly, animals were loosely maintained on the
bench surface, using a towel in order to mask the eyes and limit in-
fluences from environmental stimulations. The tips of the forceps were
placed in the middle of the hind paw and the experimenter applied
incremented force by hand until paw withdrawal. Measures were re-
peated 3 times for each hind paw during each testing session, and re-
sults were expressed as the mean (in g) of the 3 measures. For experi-
ment 3, a baseline was done before surgery. Weekly values after surgery
correspond to the average of the values for both paws.
2.5.3. Tail Flick
The tail flick reflex (experiment 2) was evaluated with a tail flick
analgesia meter (52–495, Harvard apparatus, Massachusetts, United
States). Animals were loosely maintained on the apparatus, using a
towel in order to mask the eyes and limit influences from environ-
mental stimulations. Light from the halogen lamp of the apparatus was
focused on the tail of the animal, and the tail flick reflex was auto-
matically detected and expressed as latency (seconds). The cut off time
was set at 10 s to avoid tissue damage.
2.5.4. Hot plate
The response latency to a nociceptive heat stimulus (experiment 2)
was evaluated using a hot plate (Series 8, IITC Life Science, Woodland
Hill, California). The apparatus temperature was set at 52 °C ± 0.1 °C.
The latency to the first hind paw licking or withdrawal was considered
as nociceptive response. The cut off time was set at 15 s to avoid paw
damage.
2.5.5. Dynamic hot plate
Thermal sensitivity in the dynamic hot plate (DHP) (experiment 2)
was assessed as previously described (Yalcin et al., 2009). Animals were
placed on a hot plate (BIO-CHP, Société Bioseb, Chaville, France) set at
30° ± 0.1 °C, and the plate temperature increased up to 40 °C with
1 °C.min−1 computer-controlled speed. During each degree interval,
the number of hind paw lickings, paw withdrawals and rearing was
scored. Results are expressed as number of responses for each degree
interval, and as cumulative responses between 33 and 36 °C at 5 and
14 weeks post-surgery time-points.
2.5.6. Sucrose consumption test
Before surgery, animals were habituated for 48 h to have two water
bottles on their home cages, followed by 48 h to sugar taste with two
bottles of 1% sucrose (Euromedex, France). On the test day, animals
were individually housed and underwent water deprivation at 12 AM
and were then allowed to choose between sugar and water during the
testing time period (from 6 to 7 PM). Bottles were randomly positioned
and were weighted before and after the test to evaluate sucrose con-
sumption and preference. Solution consumption over 50% of total in-
take was considered as preference for the corresponding bottle. At the
end of the experiments, the amount of water consumption (2 bottles of
water) was also evaluated during 1 h as control (experiments 2 & 3). For
experiment 3, a baseline was done before surgery.
2.6. Tissue preparation
2.6.1. Experiments 1 and 3
At the end of the experiments, rats were anaesthetized with sodium
pentobarbital overdose (Dolethal®, 800 mg/kg, Vetoquinol S.A., Lure,
France). The depth of anesthesia was controlled for by checking pedal
reflex and animals were reinjected if necessary. Heads were isolated,
and brains were collected and placed in a paraformaldehyde/glycerol
solution (4% PFA, 20% glycerol in phosphate buffer) overnight at 4 °C
and then kept at 4 °C in phosphate buffer saline solution (PBS, 0.1 M,
pH 7.4). After further cryopreservation (20% glycerol in PBS 0.1 M,
pH 7.4), coronal brain sections (40 μm) were obtained using a micro-
tome with frozen station (SM 2000 R, Leica) and were serially collected
in PBS (0.1 M, pH 7.4).
2.6.2. Experiment 2
At the end of the experiment, rats were rapidly anaesthetized with
sodium pentobarbital overdose (Dolethal®, 800 mg/kg, Vetoquinol S.A.,
Lure, France). The depth of anesthesia was controlled for by checking
pedal reflex and animals were reinjected if necessary. Using a peristaltic
pump, rats were transcardially perfused with 100 mL of phosphate
buffer (0.1 M, pH 7.4) followed by 500 mL of PFA/glutaraldehyde so-
lution (2% PFA, 0.2% glutaraldehyde in 0.2 M phosphate buffer).
Brains were collected, postfixed overnight with 2% PFA and then
cryoprotected in PBS containing 20% sucrose, frozen by immersion in
a − 45 °C isopentane bath before being stored at −80 °C until cutting.
50 μm thickness sections of both striatal and SNc levels were made by a
Leica CM3050S cryostat (LEICA microsystems, Wetzler, Germany) at
−20 °C.
2.7. Immunohistochemistry
2.7.1. Experiments 1 and 3
Immunohistochemistry was performed as previously described
(Bourdy et al., 2014). Sections were washed in PBS (3 × 10 minutes),
incubated for 20 min in a 1% H2O2/50% ethanol solution for perox-
idase extinction, washed in PBS (3 × 10 minutes), and incubated with a
solution of PBS-Triton X100 (0.3%) with donkey serum (5%) during
45 min. Then, sections were incubated overnight with a solution of PBS-
Triton X100 (0.3%) with donkey serum (1%) and the primary antibody
(NeuN, #MAB377, Millipore, 1/2500; or tyrosine hydroxylase (TH),
#MAB318, Millipore-Chemicon, 1/2000). All steps were performed on
rotary shaker at room temperature. After 3 × 10 minutes washing in
PBS, sections were incubated with a biotinylated donkey anti-mouse
secondary antibody (1/400, #BA2001, Vector Laboratories) and 1%
donkey serum for 90 min. After PBS rinsing (3 × 10 minutes), the
biotin system was amplified with the avidin-biotin-peroxidase complex
(ABC; ABC Elite, 0.2% A and 0.2% B; Vector Laboratories) in PBS
during 90 min. Sections were rinsed with 0.05 M Tris-HCl buffer (TB;
pH 7.5; 3 × 10 min) and the bound peroxidase was revealed by in-
cubation in 0.025% 3.3′-diaminobenzidine tetrahydrochloride (DAB,
Sigma), 0.0006% H₂O₂ (Sigma) in TB for approximately 5 to 10 min-
utes. The reaction was stopped by 2 × 10 minutes of TB and 2 × 10
minutes of PBS washing. Sections were then serially mounted on Su-
perfrost® slides (VWR), air-dried, dehydrated in graded alcohols baths
(1 × 70%, 1 × 95% and 2 × 100%), cleared in Roti-Histol (Carl Roth,
Karlsruhe, Germany) and coverslipped with Eukitt. Evaluation of the
lesion was performed using a Nikon Eclipse 80i microscope and pictures
were taken with a digital camera (CX 9000, MBF biosciences).
2.7.2. Experiment 2
Midbrain and striatal serial sections were processed for TH im-
munohistochemistry (Bourdenx et al., 2015). Serial free-floating sec-
tions were incubated with rabbit monoclonal TH antibody (Abcam,
#ab75875, 1/5000) for one night at room temperature and revealed by
an anti-mouse peroxidase EnVision™ system followed by DAB staining.
SNc and VTA sections were mounted on gelatinized slides, counter-
stained with a 0.1% cresyl violet solution, dehydrated and coversliped;
while striatal sections were mounted on gelatinized slides and cover-
sliped only.
2.8. Evaluation of the lesions
The extent of the tVTA and SNc lesions was evaluated by visuali-
zation of NeuN and TH immunohistochemistries repectively.
For animals of experiment 2, TH level in the striatum was semi-
quantified by comparing TH immunostaining density in sections of
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lesioned animals versus the mean density in control animals. Sections
were scanned in an Epson expression 10000XL high-resolution scanner.
Images were then analyzed in Image J software (Bethesda, MD, USA) to
measure mean grey level in the delineated striatum, as previously de-
scribed (Bourdenx et al., 2015).
TH-positive SNc or VTA cells were counted by stereology, blind with
regard to the experimental condition, using a Leica DM6000B motor-
ized microscope coupled with the Mercator Pro software (ExploraNova,
La Rochelle, France), as previously described (Bourdenx et al., 2015).
The SNc or VTA were delineated for each section and probes for ste-
reological counting were applied to the map obtained (sampling 1–6,
dissector window 80 × 60 μm, spacing 240 × 180 μm). Each TH-po-
sitive cell with its nucleus included in the probe or intersecting any of
the acceptance lines was counted. The optical fractionator method was
finally used to estimate the total number of TH-positive cells in the SNc
of each animal.
2.9. Data analysis
Results are expressed as mean ± standard error of the mean (SEM).
Statistical tests were performed using STATISTICA 13 software
(Statsoft, Tulsa, OK, USA). We used a student t-test for a two group
comparison; and multifactor analysis of variance (ANOVA) with, de-
pending on the experiment, time, speed (RPM) or temperature con-
sidered as within factors (i.e. repeated measures) and surgery groups as
between factors (i.e. independent groups), followed by Duncan post-hoc
when applicable. The significance level was set at P < .05.
3. Results
3.1. Bilateral tVTA ablation compensated motor impairment related to
partial loss of SNc dopamine cells (experiment 1)
We previously reported (Bourdy et al., 2014) that the tVTA can
modulate motor performance in a rotarod task, and that a tVTA lesion
prevented the amphetamine-induced ipsilateral rotation bias observed
after partial unilateral SNc lesion. Based on these findings, we tested
here the impact of a bilateral lesion of the tVTA on motor impairments
observed in a model of Parkinson's disease. To this end, we injected
bilaterally 6-OHDA into the SNc and/or ibotenic acid into the tVTA.
This resulted in a partial loss of dopaminergic cells in the SNc and a
large neuronal death into the tVTA, as illustrated by TH and NeuN
immunostaining respectively (Fig. 1A). Animals were trained in the
rotarod task before surgery. All of them completed the training phase,
and the effect of the lesions on motor performance was tested for three
consecutive days, 7 to 10 days after surgery. Bilateral SNc lesion in-
duced a motor deficit in the rotarod task on test days 2 and 3 compared
to sham animals (F6,60 = 23.40, P= .000119; post hoc day 2: P= .027,
day 3: P = .0086). Conversely, a bilateral tVTA lesion induced an in-
crease in motor performance over test days compared to control ani-
mals (day 2: P = .0041, day 3: P = .000038). The concomitant lesions
of the SNc and the tVTA resulted in an apparently additive effect, thus
suppressing the motor impairment by leading to performances that are
similar to the ones observed in the control group (SNc/tVTA lesion vs
sham: day 1: P= .9, day 2: P= .83, day 3: P= .19; SNc/tVTA lesion vs
SNc lesion: day 1: P= .08, day 2: P = .02, day 3: P= .001; SNc/tVTA
lesion vs tVTA lesion: day 1: P = .09, day2: P = .004, day 3:
P = .000096) (Fig. 1B, C).
3.2. Partial bilateral SNc ablation induced motor and non-motor
parkinsonian-like symptoms (experiment 2)
In Parkinson's disease, patients suffer not only from motor deficits
but also from non-motor symptoms, such as pain and depression (Faivre
et al., 2019). Before testing whether tVTA lesion may also affect these
symptoms in the lesion model of Parkinson's disease, we first
characterized the occurrence of these non-motor symptoms. The eva-
luation of the lesion conducted at the end of the experiment showed
that 6-OHDA animals displayed a partial SNc bilateral lesion (left SNc
−79.6 ± 7.5% and right SNc −84.3 ± 5% of lesion compared to
sham animals) (F1,19 = 130.38, P = 6*10−10; post hoc left:
P = .000062; right: P = .000062), associated with a partial bilateral
loss of TH-positive fibers in the striatum, as evaluated by a decrease in
grey level density (left striatum −62 ± 8.6% and right striatum
−68.3 ± 4.9%) (F1,19 = 66.77, P = 1.2*10−7; post hoc left:
P = .000066; right: P = .000066) as previously described (Gómez-Paz
et al., 2018). We also observed some loss of VTA dopamine cells (left
VTA −21.3 ± 5.9% and right VTA -17.4 ± 6.5%; overall F1,19 = 5.2,
P = .03) and a mild decrease in the TH immunostaining in the nucleus
accumbens (NAc) (left NAc −11.6 ± 2.8% and right NAc
−10.8 ± 4.5%; overall F1,19 = 4.5, P = .047), although non-sig-
nificant when considering each side (VTA: post hoc left: P= .078; right:
P = .12; NAc TH: post hoc left: P = .07; right: P = .068) (Fig. 2A).
Near the end of the experiment (12 weeks), we tested motor per-
formance using the rotarod test (Fig. 2B). Two animals (one control and
one lesion) jumped deliberately and were excluded from the results of
this test. Lesioned animals performed similarly to controls at an un-
challenging rotarod speed (5 RPM: P = .61). When rotarod speed was
increased, we observed a deficit in the lesioned rats (F1.17 = 4.73,
P = .044) compared to the unchallenging condition (5 RPM). While
lesioned animals still performed similarly to controls at 10 RPM (post
hoc: P = .92), they were significantly less performant at 15 RPM (post
hoc: P = .047) and at 20 RPM (post hoc: P = .008) (Fig. 2B).
As previously described (Sakai and Gash, 1994), the bilateral 6-
OHDA lesion induced a deficit in body weight increase (Fig. 2C)
(F1,19 = 11.72, P= .0028; post hoc week (W) 0: P= .46, W1: P= .013,
W2: P = .0019, W3: P = .0035, W4: P = .0045, W5: P = .004, W12:
P = .00021).
To test pain sensitivity, we first evaluated mechanical thresholds of
paw withdrawal using the forceps test (Luis-Delgado et al., 2006). The
SNc lesion group had lower mechanical paw withdrawal thresholds all
over the sessions compared to the control group (F1,19 = 39.53,
P= 5*10−6; post hocW2: P= .0013, W3: P= .0024, W4: P= .00028,
W5: P = .001, W12: P = .000054) (Fig. 2D). As the animal weight or
age may influence results in this test (Luis-Delgado et al., 2006), we
tested whether a relation was present between animals' weight and paw
withdrawal thresholds at each time-point. No significant correlation
was observed between the weight of animals and their mechanical
threshold for paw withdrawal (R2 comprised between 0.085 and
0.385). In order to evaluate the thermal sensitivity to heat of the ani-
mals, we performed three different tests: the tail flick test, the hot plate
test and the dynamic hot plate test. The tail flick is a spinal reflex that
can be influenced by supraspinal descending controls (Barrot, 2012). In
this test, SNc lesioned animals showed a delayed tail-flick latency at
only week 13 after surgery (F1,19 = 12.85, P = .0015; post hoc W13:
P= .00013, W2 to W12: P between 0.06 and 0.52) (Fig. 2E). In the hot
plate test (Fig. 2F) which provides a more integrated supraspinal re-
sponse, we observed a global group difference (F1,19 = 5.27, P = .03)
when including all time points together, suggesting heat hypersensi-
tivity in animals with SNc lesion. However, post hoc analysis was sig-
nificant at none of the individual time points (W2: P = .13, W3:
P = .15, W4: P = .06, W5: P = .2, W12: P = .21, W13: P = .11),
which, together with tail flick data, suggested a potential conflict be-
tween alterations in reflex and nociceptive responses. Thus, we con-
sidered using the dynamic hot plate test to have a more precise estimate
of heat sensitivity. Indeed, the slow increase in temperature allowed
minimizing the influence of reflex speed on the overall behavioral re-
sponses. In the dynamic hot plate test, SNc lesioned animals displayed a
thermal allodynia, i.e. nociceptive responses at normally non-nocicep-
tive temperatures (F1,19 = 14.29, P = .0013; post hoc: P= .05 at 35 °C
and P= .016 at 36 °C at week 14) (Fig. 2G). This thermal allodynia was
further highlighted by considering the cumulative behavioral responses
F. Faivre, et al. Neurobiology of Disease 139 (2020) 104818
4
between 33 and 36 °C (F1,19 = 21.83, P = .00017; post hoc W5:
P = .013, W14: P = .00037) (Fig. 2G).
Finally, we performed a sucrose preference test to assess anhedonia-
like behavior as symptom of depressive-like behavior. SNc lesioned
animals showed a decreased sucrose preference 4 weeks after surgery,
and a lack of preference between sucrose and water at 13 weeks post-
surgery (F1,19 = 14.59, P = .0011; post hoc W4: P = .01, W13:
P = .0022). Moreover, when the total sucrose consumption was con-
sidered, it showed that SNc lesioned animals had a decreased sucrose
consumption (F1,19 = 8.41, P = .009) at 3 (post hoc: P = .034), 5
(P = .004) and 13 weeks after surgery (P = .0076), whereas no dif-
ference in water consumption was observed (Fig. 2H).
3.3. SNc/tVTA co-ablation improved parkinsonian-like symptoms
(experiment 3)
Based on these results, we chose the most robust test for assessing
nociceptive-related responses (i.e. mechanical thresholds), and the su-
crose preference test for assessing anhedonia-like behavior, in order to
evaluate the impact of a bilateral tVTA lesion on non-motor symptoms
in the model of Parkinson's disease. As observed in the experiment 2,
animals with a bilateral SNc lesion had a lower body weight than sham
animals (F3,21 = 6.51, P= .0028; post hocW1: P= .047, W2: P= .034,
W3: P = .0067, W4: P = .0097, W5: P = .0076, W6: P = .0044, W7:
P = .0028), but also than tVTA lesioned animals at 3, 5, 6 and 7 weeks
post-surgery (W1: P= .31, W2: P= .065, W3: P= .017, W4: P= .056,
W5: P = .019, W6: P = .029, W7: P = .009) and than animals with
double lesion since week 4 (W1: P = .44, W2: P = .07, W3: P = .058,
W4: P = .004, W5: P = .004, W6: P = .0005, W7: P = .00016)
(Fig. 3B), which showed that the double lesion allowed to compensate
for body weight deficits related to SNc cell loss.
Likewise, SNc lesioned animals had a lower mechanical threshold in
the forceps test compared to sham animals, tVTA lesioned animals and
SNc/tVTA lesioned animals (F3,21 = 14.99, P = .000019; post hoc SNc
lesion vs sham, W2: P = .013, W3: P = .007, W4: P = .007, W5:
P = .00012; post hoc SNc lesion vs tVTA lesion, W2: P = .11, W3:
P = .005, W4: P = .009, W5: P = .00027; post hoc SNc lesion vs SNc/
tVTA lesion, W2: P = .004, W3: P = .00043, W4: P = .0033, W5:
P = .0062) (Fig. 3C). While tVTA lesion did not influence per se the
nociceptive response, it allowed suppressing the impact of SNc cell loss.
As observed in the experiment 2, no significant correlation was present
between the body weight of the animals and their mechanical threshold
(R2 comprised between 0.00002 and 0.27) (data not shown).
Regarding the sucrose preference test, SNc lesioned animals showed a
decreased preference for sucrose solution which became significant at
the end of the experiment (F3,21 = 3.50, P = .03; post hocW5: P= .032).
No difference was observed in the volume of water consumed
(F3,21 = 0.64, P = .60). Otherwise, the tVTA lesion and the co-lesioned
animals showed no difference when compared to control animals,
showing that double lesion compensated for SNc lesion impact (Fig. 3D).
4. Discussion
In the present study, we showed that a partial bilateral lesion of the
SNc leads to both motor and non-motor symptoms, such as lower body
weight, mechanical and thermal hypersensitivity, a potential slow-
down of the tail reflex motor response and a depressive-like symptom in
a sucrose preference test. By exploring the impact of the tVTA on those
parkinsonian-like symptoms, we further showed that the co-lesion of
the tVTA improved both motor and non-motor symptoms.
6-OHDA models have been widely used to study Parkinson's disease.
This neurotoxin causes the loss of catecholaminergic containing cell
bodies and terminals (Ungerstedt, 1968) by the production of reactive
oxygen species. Noradrenergic and serotoninergic neuroprotection may
be used to obtain exclusive dopamine cell damage; however, it has been
suggested that models without such neuroprotection might provide
better modelling of Parkinson's disease (Bezard et al., 2013). 6-OHDA
has mostly been injected unilaterally, into the SNc or the medial fore-
brain bundle, to elicit the loss of dopamine neurons in animals. Con-
versely, partial bilateral lesion better mimic the neuropathy of Par-
kinson's disease in human in which there is usually an incomplete
bilateral destruction of dopamine neurons in the SNc (German et al.,
1989) and a more limited loss of some sensitive neurons in the VTA
(Alberico et al., 2015). However, such bilateral lesion may cause
aphagia and adipsia, leading to decreased body weight and even the
death of the animals (Bezard and Przedborski, 2011; Bové et al., 2005;
Dauer and Przedborski, 2003). The partial bilateral SNc lesion com-
bined with careful postsurgical care, including rehydration with saline











































































Fig. 1. Motor performance in the rotarod task after bilateral SNc and/or tVTA lesion. Animal underwent SNc lesion (6-OHDA) and/or tVTA excitotoxic lesion
(ibotenic acid). 7 to 10 days after the lesion, motor performance was tested in the rotarod test. (A) Histological evidence for bilateral SNc and tVTA lesion with TH
and NeuN immunostaining respectively. Scale bars, TH pictures = 1 mm; NeuN pictures = 400 μm. (B) Latency to fall is altered in animals with SNc or tVTA lesion
but not in animals with concomitant bilateral SNc/tVTA lesion. (C) Individual distribution of latency to fall on the third test day. Values are presented as
mean ± SEM. (*, P < .05; **, P < .01; ***, P < .005). The number of animals is given between brackets. Scatter plots indicate individual data points.
Abbreviation: NeuN, neuronal nuclei; SNc, substantia nigra pars compacta; TH, tyrosine hydroxylase; tVTA, tail of the ventral tegmental area.
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Regarding the motor symptoms, the bilateral lesion of the SNc in-
duced the expected motor impairment in the rotarod task. Beside this
motor influence, we also explored the impact of SNc lesion on some
non-motor symptoms of Parkinson's disease (Faivre et al., 2019). The
animals displayed lower mechanical nociceptive thresholds as assessed
using digital forceps, which is similar to previous reports with other
models and tests (Domenici et al., 2019; Gee et al., 2015; Zengin-Toktas
et al., 2013), although some authors described that this effect may be
time-dependent (Cao et al., 2016; Wang et al., 2017) or even side-de-
pendent in case of unilateral lesion (Takeda et al., 2014). We also
Fig. 2. Effect of bilateral SNc lesion on motor and non-motor symptoms. Rats underwent SNc lesion (6-OHDA) and consequences were tested on motor (rotarod) and
non-motor symptoms (body weight, digital forceps, tail flick, hot plate, dynamic hot plate and sucrose preference). (A) The bilateral partial lesion of the SNc led to a
partial TH loss in the striatum. Scale bars, 1 mm. (B) SNc lesioned animals displayed motor deficits in the rotarod task (15 and 20 RPM). (C) The body weight of SNc
lesioned animals remained lower than sham animals along the experiment. (D) SNc lesioned animals had a lower mechanical nociceptive threshold in a digital
forceps test. (E) SNc lesioned animals showed a mild slowdown of the withdrawal response in the tail flick test, but a tendency at each test day for faster response in
the classical hot plate test (F). (G) In the dynamic hot plate test, SNc lesioned animals respond to lower temperature than sham animals (left panel). Likewise, the
comparison of the cumulative responses observed between 33 °C and 36 °C showed that lesioned animals exhibited higher number of nociceptive responses at
normally non-nociceptive temperatures than control animals (right panel). (H) In a two-bottle-choice paradigm, lesioned animals showed a lower preference to
sucrose solution (1%) compared to sham animals at 4 and 13 weeks after surgery (left panel). They also showed a decrease in sucrose consumption volume at 3, 5 and
13 weeks (middle panel) but not in water consumption (right panel). The number of animals is given between brackets. Values are presented as mean ± SEM (note
that some SEMs are smaller than the symbol diameter, as for body weight for example). (*, P < .05; **, P < .01; ***; P < .005).
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assessed heat sensitivity but obtained some contradictory results, with
an apparent hyposensitivity in the tail flick test, a tendency to hy-
persensitivity in the hot plate test and a thermal allodynia in the dy-
namic hot plate. Interestingly, such discrepancies also exist in the lit-
erature, particularly concerning the tail flick test for which results vary
depending on the model, species and test procedure (Domenici et al.,
2019; Faivre et al., 2019; Gee et al., 2015; Gómez-Paz et al., 2018;
Greco et al., 2008; Grossmann et al., 1973; Nascimento et al., 2018;
Ogata et al., 2015; Park et al., 2015; Tassorelli et al., 2007). Concerning
the hot plate test, it has been documented that the response latency is
decreased in 6-OHDA models of Parkinson's disease (Chen et al., 2013;
Dolatshahi et al., 2015; Gee et al., 2015; Lin et al., 1981; Nascimento
et al., 2018; Saadé et al., 1997). An explanation for these differences
between tests may be related to the spinal reflex component of the tail
flick, which is predominant in this test and influenced by descending
supraspinal controls. The motor slow-down accompanying Parkinson's
disease (Low et al., 2002; Mazzoni et al., 2012) and its models (Lindner
et al., 1999; Santana et al., 2015) may thus mask in some protocols the
nociceptive hypersensitivity. This technical limitation can however be
overcome by using a slow ramp of temperature increment and by
looking at the number of nociceptive responses instead of latencies.
This procedure thus allowed us detecting thermal allodynia (i.e. a pain-
related response due to a stimulus that does not normally provoke pain)
in the 6-OHDA lesioned animals. Finally, we assessed a symptom as-
sociated with depressive-like behaviors in animals, by using a sucrose
preference test, and we observed a decreased preference with 6-OHDA
lesion, in agreement with literature reports (Carvalho et al., 2013; Ilkiw
et al., 2019; Kamińska et al., 2017; Liu et al., 2015; Matheus et al.,
2016; Santiago et al., 2010, 2014; Silva et al., 2016; Tadaiesky et al.,
2008; Vecchia et al., 2018). This effect was however time dependent
(Matheus et al., 2016; Santiago et al., 2010), and displayed some
variability from one experiment to the other, which required an ap-
propriate time-window to detect it and thus makes it more challenging
to systematically assess in the animal model. A motor impairment
consecutive to 6-OHDA lesion could potentially also impair swallowing,
which could then affect fluid intake (and thus sucrose consumption)
and also lead to the body weight loss observed. However, at the con-
sidered time-points, the total amount of water consumed was equiva-
lent between the experimental groups, supporting the fact that the
observed decrease in sucrose preference was not a simple consequence
of motor deficits.
Following co-lesion of the tVTA and the SNc, we observed that
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Fig. 3. Effect of bilateral tVTA lesion on non-motor symptoms in a model of Parkinson's disease. Animal underwent SNc lesion (6-OHDA) and/or tVTA excitotoxic
lesion (ibotenic acid). The impact was studied on body weight, on nociceptive response to digital forceps and in the sucrose preference test. (A) The bilateral partial
lesion of the SNc, but not of the tVTA alone, led to a partial TH loss in the striatum and the midbrain. Scale bars, 1 mm. (B) The body weight of SNc lesioned animals
remained lower than other groups along the experiment. Animals with SNc and tVTA co-lesions showed similar body weight as control animals. (C) SNc lesioned
animals showed lower mechanical nociceptive thresholds in the digital forceps test at all considered time points, which was compensated by concomitant lesion of the
tVTA. (D) SNc lesioned animals showed a lower preference to sucrose compared to sham animals at 5 weeks after surgery (left panel), and a tendency to decreased
overall sucrose (middle panel) but not water (right panel) consumption. As for other tests, the tVTA bilateral lesion compensated sucrose preference in SNc lesioned
animals. The number of animals is given between brackets. Values are presented as mean ± SEM (note that some SEMs are smaller than the symbol diameter, as for
body weight for example). (*, P < .05; **, P < .01; ***; P < .005).
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animals exhibited the same motor performance, weight increase, no-
ciceptive mechanical threshold and sucrose preference as control ani-
mals.
The bilateral lesion of the tVTA increased per se the motor perfor-
mance of the animals at days 2 and 3 of rotarod testing, showing that
the tVTA controls motor behaviors. This is in agreement with our
previous report concerning the impact of tVTA lesion on motor per-
formance and motor skill learning, which supports a main role of the
tVTA as a GABA brake for the nigrostriatal pathway (Bourdy et al.,
2014). The tVTA control over SNc dopamine neurons has been de-
monstrated by using neuroanatomical (Bourdy et al., 2014; Ferreira
et al., 2008; Jhou et al., 2009a, 2009b; Kaufling et al., 2010a) and in
vivo electrophysiological approaches (Bourdy et al., 2014), thus high-
lighting a tVTA-nigrostriatal pathway and the inhibitory influence of
the tVTA on the activity of SNc dopamine neurons. Indeed, the elec-
trical/chemical stimulation and chemical inhibition of the tVTA de-
creased and increased, respectively, the activity of the SNc dopamine
neurons (Bourdy et al., 2014). Dopamine cells being under the control
of excitatory and inhibitory inputs that regulate their activity (Gantz
et al., 2018; Morikawa and Paladini, 2011), suppressing the inhibitory
influence of the tVTA on dopamine cells may facilitate excitatory im-
pact and promote activity of these cells. Accordingly, the bilateral le-
sion of the tVTA has been shown to increase the basal activity of the
SNc dopamine neurons (Bourdy et al., 2014), even though no locomotor
hyperactivity was present following such lesion (Bourdy et al., 2014;
Jhou et al., 2009a). Such inhibitory control is also supported by pre-
vious findings showing that an unilateral lesion of the tVTA elicited an
amphetamine-induced contralateral rotation bias, and compensated for
the ipsilateral bias in animal with unilateral SNc lesion (Bourdy et al.,
2014). In the present study, the concomitant bilateral lesion of the tVTA
in animals with a bilateral partial SNc lesion improved motor perfor-
mance, leading to similar level of motor performance as controls in the
rotarod task. After SNc lesion, this action of tVTA lesion could be re-
lated to the loss of the inhibitory brake on the surviving dopamine
neurons, and to the strong overlap of the terminal field of individual
dopamine neurons within the striatal complex. Indeed, a single SNc
neuron can, by its profuse arborisation (Gauthier et al., 1999; Matsuda
et al., 2009; Prensa and Parent, 2001), cover up to 5.7% of the total
volume of the striatum (Matsuda et al., 2009).
To assess tVTA influence on non-motor symptoms in the 6-OHDA
model, we selected 3 parameters: the body weight, the mechanical
nociceptive response assessed by the digital forceps test, and the su-
crose preference test for the depressive-like behavior. The lesion of the
tVTA had, per se, no impact on these parameters in animals with intact
dopamine systems. It suggests that this brain region may not be es-
sential to these functions and behaviors. It can however modulate them.
Indeed, the tVTA lesion counterbalanced the weight loss, mechanical
hypersensitivity and sucrose anhedonia in animals with bilateral SNc
lesion, showing that tVTA can notably influence non-motor symptoms
associated with partial loss of dopamine cells. The link between
Parkinson's disease and weight loss in animal models has been asso-
ciated with lower density of nigrostriatal dopamine neurons (Lee et al.,
2016) and decreased striatal dopaminergic activity (Pak et al., 2018).
Moreover, a low intensity deep brain stimulation of the tVTA sig-
nificantly decreases rat's food intake (Melse et al., 2016). Un-
fortunately, we did not measure food intake itself throughout the ex-
periments, which could have provided interesting information to relate
to body weight changes. The influence of dopamine systems on noci-
ceptive responses is also well established. Indeed, activation of meso-
limbic neurons can mediate a suppression of tonic pain (Altier and
Stewart, 1999; Wood, 2008), and the application of a dopamine D2
receptor agonist into the NAc has an antinoceptive action in the for-
malin test (Taylor et al., 2003). Moreover, the acute inhibition of the
tVTA can have an analgesic action in the formalin test (Jhou et al.,
2012), and the control of dopamine neurons by the tVTA is altered in a
context of neuropathic pain (Sagheddu et al., 2015). Dopamine activity
is also altered in animal models of depression (Kaufling, 2019), and
anatomical data and experimental evidence have also related the tVTA
with depressive-like behaviors. Indeed, shocks provided according to a
procedure usually leading to learned helplessness led to Fos induction
in the tVTA (Brown and Shepard, 2013) and the lesion of this brain
region decreased the number of escape failures (Brown and Shepard,
2013; Elmer et al., 2019). The loss of the tonic inhibitory control that
the tVTA exerts on dopamine neurons (as well as on some serotonergic
neurons) could contribute to the compensatory effect observed on these
symptoms in the model of Parkinson's disease.
The present study provides behavioral evidence for a main influence
of the tVTA on the expression of motor and non-motor symptoms re-
lated to partial loss of dopamine cells. While a co-lesional approach
would be of poor therapeutic interest, the recent report of the molecular
profile of the tVTA (Smith et al., 2019) may open other options. It might
indeed help looking for potential pharmacological targets that could
help modulating tVTA activity and thus positively influence symptoms
in Parkinson's disease.
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